Lixisenatide

• • emerging
    Claim: Lixisenatide slowed motor disability progression over 12 months in early Parkinson's disease (phase 2) standing
  • resolved

  Trial of Lixisenatide in Early Parkinson's Disease.

  Meissner WG, Remy P, Giordana C, Maltête D, Derkinderen P, Houéto JL, Anheim M, Benatru I, Boraud T, Brefel-Courbon C, Carrière N, Catala H, Colin O, Corvol JC, Damier P, Dellapina E, Devos D, Drapier S, Fabbri M, Ferrier V, Foubert-Samier A, Frismand-Kryloff S, Georget A, Germain C, Grimaldi S, Hardy C, Hopes L, Krystkowiak P, Laurens B, Lefaucheur R, Mariani LL, Marques A, Marse C, Ory-Magne F, Rigalleau V, Salhi H, Saubion A, Stott SRW, Thalamas C, Thiriez C, Tir M, Wyse RK, Benard A, Rascol O, LIXIPARK Study Group

  pmid 38598572

• • established
    Claim: Lixisenatide was cardiovascularly neutral after acute coronary syndrome in type 2 diabetes (ELIXA) standing
  • resolved

  Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.

  Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, Riddle MC, Solomon SD, Tardif JC, ELIXA Investigators

  pmid 26630143

A claim's standing is its latest row in an append-only history; a tombstone names the later evidence and the reason. The Graveyard and the Resurrection Yard.